middle.news
AdAlta Raises A$2.5M to Advance CAR-T Therapy BZDS1901 with FDA and Manufacturing Milestones
10:14am on Monday 4th of May, 2026 AEST
•
Biotechnology
Read Story
AdAlta Raises A$2.5M to Advance CAR-T Therapy BZDS1901 with FDA and Manufacturing Milestones
10:14am on Monday 4th of May, 2026 AEST
Key Points
A$2.5 million placement at A$0.004 per share with attaching options
Funds to support US FDA pre-IND guidance and Australian manufacturing transfer
BZDS1901 shows rare complete tumour clearance in advanced mesothelioma patients
Geopolitical shifts increase value of Australian manufacturing and regulatory platform
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
AdAlta (ASX:1AD)
OPEN ARTICLE